Key result
Nonstatin therapies acting via LDL receptor upregulation match statins in cutting major vascular events.
Why the study?
Does lowering LDL-C via statin and nonstatin therapies that upregulate LDL receptor expression reduce major vascular events?
Does lowering LDL-C via statin and nonstatin therapies that upregulate LDL receptor expression reduce major vascular events?
Answers are grounded in this paper and cite their sources.
Both statin and nonstatin therapies that upregulate LDL receptor expression yield similar reductions in major vascular events per unit reduction in LDL-C, and lower achieved LDL-C levels correspond to lower rates of major coronary events.
In this meta-regression analysis, the use of statin and nonstatin therapies that act via upregulation of LDL receptor expression to reduce LDL-C were associated with similar RRs of major vascular events per change in LDL-C. Lower achieved LDL-C levels were associated with lower rates of major coronary events.
No takes yet. Share an insight, caveat, or question.
Silverman et al. (2016) studied this question. Statin and nonstatin therapies acting via LDL receptor upregulation were associated with similar relative risk reductions of major vascular events per change in LDL-C.
Synapse has enriched 10 related papers. Consider them for comparative context: